✦ LIBER ✦

Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium : A Phase II trial of the Minnie Pearl Cancer Research Network

✍ Scribed by John D. Hainsworth; Anthony A. Meluch; Sharlene Litchy; Frederick M. Schnell; James D. Bearden; Kathleen Yost; F. Anthony Greco

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 76 KB
Volume: 103
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21078

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paclitaxel, carboplatin, and topotecan i

Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma : A Phase II trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Lisa H. Morrissey; Daniel C. Scullin Jr.; Gerry Ann Houston; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the feasibility, toxicity, and efficacy of a novel three‐drug regimen containing paclitaxel, carboplatin, and topotecan followed by oral etoposide in the first‐line treatment of patients with small cell lung carcinoma. ## METHO

Gemcitabine and vinorelbine in the secon

Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients : A Minnie Pearl Cancer Research Network Phase II trial

✍ John D. Hainsworth; Howard A. Burris III; Sharlene Litchy; Joan B. Erland; Jerem 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## BACKGROUND. Second-line chemotherapy for patients with nonsmall cell lung carcinoma has been ineffective due to the lack of activity of older agents following platinum-based therapy. This Phase II trial evaluated the feasibility, toxicity, and efficacy of two active new agents, gemcitabine and v

Weekly docetaxel in the treatment of eld

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A Minnie Pearl Cancer Research Network Phase II Trial

✍ John D. Hainsworth; Howard A. Burris III; Sharlene Litchy; Lisa H. Morrissey; Jo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 3 views

## Background: Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. in the current phase ii trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatme

Weekly docetaxel with either gemcitabine

Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma : Phase II trials of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Howard A. Burris III; Frederic T. Billings III; James E. Bra 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 3 views

A carboplatin-based regimen for the trea

A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium

✍ Eric J. Small; Linda J. Fippin; Mary Lou Ernest; Peter R. Carroll 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 622 KB

## EIACKGROUND. Many patients with advanced transitional cell carcinoma are unable to receive cisplatin-based therapy. The efficacy and toxicity of a carboplatin-based regimen in the treatment of patients with advanced transitional cell carcinoma was therefore evaluated. ## METHODS. Twenty-thre

Phase I/II trial of paclitaxel by 1-hour

Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ John D. Hainsworth; Howard A. Burris III; Joan B. Erland; Lisa H. Morrissey; Ant 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 3 views

## BACKGROUND. The combination of paclitaxel and carboplatin is widely used in the treatment of patients with advanced nonsmall cell lung carcinoma. In this Phase I/II study the authors evaluated the feasibility, toxicity, and efficacy of adding a third active antineoplastic agent, gemcitabine, to